Multicentre, randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of the thromboprophylaxis with bemiparin 3,500 IU/d for 28 days compared to 8 days, in patients undergoing oncological abdominal/pelvic surgery

Trial Profile

Multicentre, randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of the thromboprophylaxis with bemiparin 3,500 IU/d for 28 days compared to 8 days, in patients undergoing oncological abdominal/pelvic surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Bemiparin sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CANBESURE
  • Most Recent Events

    • 30 Apr 2010 Results have been published in the Journal of Thrombosis and Haemostasis.
    • 13 Jul 2009 Results were presented during a late-breaking clinical trial session at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 13 Jul 2009 Primary composite endpoint (deep vein thrombosis, pulmonary embolism, death rate) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top